Basilea Pharmaceutica AG / Fundamentals
Income statement
- Net revenue
€391.93M - Cost of goods sold
€116.69M - Gross profit
€275.24M - SG&A expenses
€69.64M - R&D expenses
€165.89M - EBITDA
€99.14M - D&A
€5.25M - EBIT
€86.03M - Interest expenses
€16.65M - EBT
€75.69M - Tax expenses
-€18.54M - Net income
€94.24M
Cash flow statement
- Net deferred tax
-€5.11M - Non-cash items
-€12.49M - Changes in working capital
-€1.03M - Operating cash flow
€94.84M - Capex
€2.94M - Other investing cash flow
€511.61K - Net investing cash flow
-€2.19M - Total cash dividends paid
€0.00 - Issuance of common stock
€5.13M - Debt repayment
-€36.43M - Other financing cash flow
-€39.00M - Net financing cash flow
-€75.42M - Foreign exchange effects
-€108.10K - Net change in cash
-€25.77M - Cash at end of period
€0.00 - Free cash flow
€97.78M
Balance sheet
- Cash and cash equivalents
€129.19M - Cash and short-term investments
€129.20M - Total receivables
€60.55M - Inventory
€33.83M - Other current assets
€12.86M - Total current assets
€236.45M - Property, plant & equipment
€20.34M - Goodwill
€0.00 - Intangible assets
€400.30K - Long-term investments
-€23.55K - Other non-current assets
€156.27K - Total non-current assets
€39.44M - Total assets
€275.89M - Accounts payable
€12.29M - Short-term debt
€2.21M - Other current liabilities
€34.26M - Total current liabilities
€48.76M - Long-term debt
€117.32M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€23.12M - Total non-current liabilities
€140.43M - Total liabilities
€189.20M - Common stock
€14.10M - Retained earnings
-€988.22M - Other equity
€0.00 - Total equity
€86.69M - Total liabilities and shareholders' equity
€275.89M
Company information
- Market capitalization
€625.21M - Employees
164 - Enterprise Value
€622.97M
Company ratios
- Gross margin
-
70.2% Much better than peer group: -130.9% - EBITDA margin
-
25.3% Much better than peer group: -1,013.0% - EBIT margin
-
22.0% Much better than peer group: -1,114.3% - EBT margin
-
19.3% Much better than peer group: -1,116.9% - Net margin
-
24.0% Much better than peer group: -1,114.7% - ROE
-
108.7% Much better than peer group: -419.5% - ROA
-
34.2% Much better than peer group: -83.4% - Asset turnover
-
142.1% Much better than peer group: 23.3% - FCF margin
-
23.4% Much better than peer group: -945.7% - FCF yield
14.7% - Efficiency ratio
74.7% - Net sales per employee
-
€2.39M - Net income per employee
-
€574.61K